NASDAQ:BLRX

BioLineRx (BLRX) Stock Forecast, Price & News

$1.63

+0.03 (+1.88%)

(As of 08:57 AM ET)

Compare

Today's Range: $1.63
▼
$1.63
50-Day Range: $1.23
▼
$2.45
52-Week Range: $0.55
▼
$2.53

Volume: 8,442 shs
Average Volume: 643,658 shs
Market Capitalization: $100.29 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $21.00

BioLineRx MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,212.5% Upside
$21.00 Price Target
Short Interest: Bearish
7.26% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.77
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.83) to ($0.30) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.83 out of 5 stars

Medical Sector

812th out of 966 stocks

Pharmaceutical Preparations Industry

378th out of 446 stocks

3.5

Analyst's Opinion

Consensus Rating
BioLineRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $21.00, BioLineRx has a forecasted upside of 1,212.5% from its current price of $1.60.
Amount of Analyst Coverage
BioLineRx has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
7.26% of the outstanding shares of BioLineRx have been sold short.
Short Interest Ratio / Days to Cover
BioLineRx has a short interest ratio ("days to cover") of 4.1.
Change versus previous month
Short interest in BioLineRx has recently increased by 86.25%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
BioLineRx does not currently pay a dividend.
Dividend Growth
BioLineRx does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BLRX.

3.8

News and Social Media Coverage

News Sentiment
BioLineRx has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for BioLineRx this week, compared to 1 article on an average week.
Search Interest
42 people have searched for BLRX on MarketBeat in the last 30 days. This is an increase of 68% compared to the previous 30 days.
MarketBeat Follows
17 people have added BioLineRx to their MarketBeat watchlist in the last 30 days. This is an increase of 1,600% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BioLineRx insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.10% of the stock of BioLineRx is held by insiders.
Percentage Held by Institutions
Only 2.01% of the stock of BioLineRx is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for BioLineRx are expected to grow in the coming year, from ($0.83) to ($0.30) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of BioLineRx is -2.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of BioLineRx is -2.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
BioLineRx has a P/B Ratio of 1.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About BioLineRx (NASDAQ:BLRX) Stock

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; and MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer, as well as licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Modi'in, Israel.

BLRX Price History

30 days | 90 days | 365 days | Advanced Chart

BLRX Stock News Headlines

September 28, 2023 | msn.com

BioLineRx Touts Encouraging Data From Therapy Trial For First Line Pancreatic Cancer

September 26, 2023 | americanbankingnews.com

BioLineRx (NASDAQ:BLRX) Stock Crosses Above 200 Day Moving Average of $1.43

October 4, 2023 | Edge On The Street (Ad)

The Strategic Gold Play You Haven't Heard About

Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.

September 19, 2023 | finance.yahoo.com

BioLineRx Announces Acceptance of Oral Presentation on Pilot Phase Data from Phase 2 Combination Clinical Trial with Motixafortide in First-Line PDAC at AACR Special Conference on Pancreatic Cancer

September 18, 2023 | msn.com

Assessing BioLineRx As A Buy After Drug Approval

September 14, 2023 | finance.yahoo.com

BLRX: …Go!

September 13, 2023 | bizjournals.com

Waltham-headquartered BioLineRx gets FDA approval for cancer drug

September 12, 2023 | bizjournals.com

Publicly traded biotech firm BioLineRx gets FDA approval for cancer drug with help from Washington University

October 4, 2023 | Edge On The Street (Ad)

The Strategic Gold Play You Haven't Heard About

September 11, 2023 | marketwatch.com

BioLineRx Shares Climb 22% After FDA Approves Aphexda With Filgrastim

September 11, 2023 | proactiveinvestors.com

BioLineRx rallies on FDA approval of Aphexda with Filgrastim

September 11, 2023 | markets.businessinsider.com

BioLineRx: FDA Approves APHEXDA Plus Filgrastim To Mobilize Hematopoietic Stem Cells; Stock Up

September 11, 2023 | finance.yahoo.com

BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma

September 5, 2023 | finance.yahoo.com

BLRX: On Your Marks, Get Set…

August 31, 2023 | finance.yahoo.com

BioLineRx Ltd. (NASDAQ:BLRX) Q2 2023 Earnings Call Transcript

August 30, 2023 | finanznachrichten.de

BioLineRx Ltd: BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates

August 30, 2023 | seekingalpha.com

BioLineRx GAAP EPS of -$0.02

August 30, 2023 | markets.businessinsider.com

Bioline RX Ltd Sponsored ADR (BLRX) Receives a Buy from H.C. Wainwright

August 30, 2023 | finance.yahoo.com

BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates

August 22, 2023 | investing.com

BioLineRx (BLRX) Earnings Dates & Reports

August 22, 2023 | finance.yahoo.com

BioLineRx to Report Second Quarter 2023 Results on August 30, 2023

July 17, 2023 | finance.yahoo.com

BioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase; Combination Trial Includes Investigational Candidate Motixafortide

June 7, 2023 | finance.yahoo.com

BLRX: First Quarter Results

May 24, 2023 | finance.yahoo.com

BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates

May 23, 2023 | seekingalpha.com

biolinerx Q1 2023 Earnings Preview

May 17, 2023 | finance.yahoo.com

BioLineRx to Report First Quarter 2023 Results on May 24, 2023

May 10, 2023 | investing.com

BioLine RX Ltd (BLRX)

See More Headlines

Receive BLRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLineRx and its competitors with MarketBeat's FREE daily newsletter.

BLRX Company Calendar

Last Earnings: 8/30/2023
Today: 10/04/2023
Next Earnings (Estimated): 11/21/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BLRX
CUSIP: N/A
CIK: 1498403
Web: www.biolinerx.com
Phone: (728) 642-9100
Fax: 972-8642-9101
Employees: 49
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $21.00
High Stock Price Forecast: $21.00
Low Stock Price Forecast: $21.00
Forecasted Upside/Downside: +1,212.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.69)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-24,950,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -103.97%
Return on Assets: -60.62%

Debt

Debt-to-Equity Ratio: 0.40
Current Ratio: 2.79
Quick Ratio: 2.79

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.83 per share
Price / Book: 1.93

Miscellaneous

Outstanding Shares: 61,530,000
Free Float: 60,854,000
Market Cap: $98.45 million
Optionable: Not Optionable
Beta: 1.75

The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. Philip A. Serlin CPA (Age 63)
M.B.A., CPA, MBA, Chief Exec. Officer
Comp: $635k

Ms. Mali Zeevi CPA (Age 47)
CPA, Chief Financial Officer
Comp: $380k

Dr. Ella Sorani (Age 55)
Chief Devel. Officer
Comp: $457k

Ms. Holly W. May M.B.A. (Age 61)
Pres of BioLineRx USA
Comp: $328k

Mr. John Lacey
Head of Corp. Communications & Investor Relations

Mr. Adam Janoff Esq.
Gen. Counsel & Head of Compliance

Ms. Tsipi Keren-Lehrer B.Sc.
L.L.B., Head of BD & Strategic Advisor

Mr. Raziel Fried
Treasurer & Budgetary Control Director

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

BLRX Stock - Frequently Asked Questions

Should I buy or sell BioLineRx stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioLineRx in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BLRX shares.
View BLRX analyst ratings or view top-rated stocks.
What is BioLineRx's stock price forecast for 2023?: 1 Wall Street analysts have issued 1 year price targets for BioLineRx's shares. Their BLRX share price forecasts range from $21.00 to $21.00. On average, they anticipate the company's share price to reach $21.00 in the next twelve months. This suggests a possible upside of 1,212.5% from the stock's current price.
View analysts price targets for BLRX or view top-rated stocks among Wall Street analysts.
How have BLRX shares performed in 2023?: BioLineRx's stock was trading at $0.59 at the beginning of the year. Since then, BLRX shares have increased by 171.2% and is now trading at $1.60.
View the best growth stocks for 2023 here.
Are investors shorting BioLineRx?: BioLineRx saw a increase in short interest in September. As of September 15th, there was short interest totaling 4,470,000 shares, an increase of 86.3% from the August 31st total of 2,400,000 shares. Based on an average daily trading volume, of 1,090,000 shares, the days-to-cover ratio is currently 4.1 days.
View BioLineRx's Short Interest.
When is BioLineRx's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 21st 2023.
View our BLRX earnings forecast.
How were BioLineRx's earnings last quarter?: BioLineRx Ltd. (NASDAQ:BLRX) released its earnings results on Wednesday, August, 30th. The biotechnology company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.16) by $0.14. During the same quarter last year, the firm posted ($0.16) EPS.

What other stocks do shareholders of BioLineRx own?: Based on aggregate information from My MarketBeat watchlists, some companies that other BioLineRx investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), KushCo (KSHB), Aeterna Zentaris (AEZS), CNBX Pharmaceuticals (CNBX), Pennsylvania Real Estate Investment Trust (PEI), Savara (SVRA), Bionano Genomics (BNGO) and Gran Tierra Energy (GTE).
What is BioLineRx's stock symbol?: BioLineRx trades on the NASDAQ under the ticker symbol "BLRX."
How do I buy shares of BioLineRx?: Shares of BLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is BioLineRx's stock price today?: One share of BLRX stock can currently be purchased for approximately $1.60.
How much money does BioLineRx make?: BioLineRx (NASDAQ:BLRX) has a market capitalization of $98.45 million. The biotechnology company earns $-24,950,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis.
How can I contact BioLineRx?: BioLineRx's mailing address is 2 HAMA-AYAN STREET, MODI-IN L3, 7177871. The official website for the company is www.biolinerx.com. The biotechnology company can be reached via phone at (728) 642-9100, via email at ir@biolinerx.com, or via fax at 972-8642-9101.

This page (NASDAQ:BLRX) was last updated on 10/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial